ClinicalTrials.gg
CompletedNCT02569541Updated Jan 30, 2020Results posted

Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections

A Phase 2/3 interventional study of sodium fusidate in Refractory Bone or Joint Infections, sponsored by Arrevus Inc.. Completed at 19 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-01-30.

Sponsored by Arrevus Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 37 studies in Osteomyelitis with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Osteomyelitis · United States.

Enrollment
19th of 28
30 · median 41
Started
2015
with 2 others
Phase 2/3
Only one
of the 37
Registered
21st of 37
by date
Lead sponsor
1 of 37
Arrevus Inc.

Among the 37 studies in Osteomyelitis with a site in United States, this one is the 19th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2015, is the only one in phase 2/3, and was the 21st registered.

Osteomyelitis

105 studies on the registry are indexed under Osteomyelitis; 30 are open to participants now.

Browse Osteomyelitis studies →

Open to participants now

5 of the 37 studies in Osteomyelitis with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Osteomyelitis studies recruiting now, 14 (61%) set no upper age limit and 7 (30%) stop at 75 or younger; 6 take children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Osteomyelitis with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety and effectiveness of oral sodium fusidate (CEM-102) as chronic antibiotic for the treatment of bone or joint infections.

Read the detailed description

Prospective, open-label, non-randomized, single-arm trial to evaluate the safety and effectiveness of CEM-102 for chronic antibiotic suppressive therapy of bone or joint infections. Subjects enrolling in this study must have a refractory staphylococcal bone or joint infection that requires suppressive antibiotic therapy (e.g. having an infection that cannot be managed by complete removal of the infected bone or foreign material, a refractory infection not responding to previous treatment, or not being a candidate for long-term intravenous antibiotic therapy).

03

Conditions studied

  • Refractory Bone or Joint Infections

Browse trials for

Keywords

  • fusidic acid
  • prosthetic joint infections
  • bone infections
  • osteomyelitis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents between 12 and 18 years must weigh >60 kg
  • Bone or joint infection due to an inclusionary pathogen demonstrated from a culture from samples obtained within 6 weeks prior to enrollment
  • Not a candidate, as determined by the Investigator, for suitable alternative therapy
  • After completion of 1-2 weeks of the companion antibiotic, must be a suitable candidate for CEM-102 monotherapy for chronic treatment

Exclusion criteria

Exclusion Criteria:

  • Requires concomitant treatment with OATP1B1 and OATP1B3 substrates, in particular, statins (HMG-CoA reductase inhibitors)
  • Known severe renal impairment, as indicated by estimated \<30 mL/min (by Cockcroft-Gault calculation)
  • Evidence of significant liver disease: >3 × or direct >ULN; known cirrhosis with decompensation (i.e. Class B or C disease)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    CEM-102 (Sodium fusidate)

    1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy: * 6 months of treatment; or * 24 months of treatment (if continued on chronic suppressive therapy)

    Drug: sodium fusidate

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Success at 6 Months

    Number of participants in the intent to treat (ITT) analysis set who meet all the criteria for clinical success at the 6-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia

    Time frame: 6 months after start of treatment

Secondary outcomes

  1. Safety and Tolerability

    Number of participants with TEAEs, SAEs, deaths, and discontinuations due to AEs. Treatment-emergent adverse events, defined as events with a start date on or after the initiation of study drug through 28 days after the last dose of study drug, are reported.

    Time frame: Entire study period - up to 24 months

  2. Clinical Success at 9 Months

    Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 9-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia

    Time frame: 9 months after start of treatment

  3. Clinical Success at 12 Months

    Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 12-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia

    Time frame: 12 months after start of treatment

  4. Clinical Success at 15 Months

    Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 15-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia

    Time frame: 15 months after start of treatment

  5. Clinical Success at 18 Months

    Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 18-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia

    Time frame: 18 months after start of treatment

  6. Clinical Success at 21 Months

    Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 21-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia

    Time frame: 21 months after start of treatment

  7. Clinical Success at 24 Months

    Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 24-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia

    Time frame: 24 months after start of treatment

07

Results

Posted Jan 30, 2020

Participant flow

Participant flow — Overall Study
MilestoneCEM-102 (Sodium Fusidate)
Started30
Completed9
Not completed21

Outcome measures

PrimaryClinical Success at 6 Months

Number of participants in the intent to treat (ITT) analysis set who meet all the criteria for clinical success at the 6-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia

Time frame:
6 months after start of treatment
Reported as:
Count of participants · Participants
Clinical Success at 6 Months
ParticipantsCEM-102 (Sodium Fusidate)
Clinical Success18
Clinical Failure9
Indeterminate3
SecondarySafety and Tolerability

Number of participants with TEAEs, SAEs, deaths, and discontinuations due to AEs. Treatment-emergent adverse events, defined as events with a start date on or after the initiation of study drug through 28 days after the last dose of study drug, are reported.

Time frame:
Entire study period - up to 24 months
Reported as:
Count of participants · Participants
Safety and Tolerability
ParticipantsCEM-102 (Sodium Fusidate)
Treatment Emergent AE (TEAE)29
Severe TEAE12
TEAE Related to Study Drug7
TEAE Leading to Study Discontinuation9
TEAE Leading to Study Drug Discontinuation12
TE Serious Adverse Event (SAE)15
TE SAE with outcome of death0
TE SAE Related to Study Drug0
TE SAE Leading to Study Discontinuation7
TE SAE Leading to Study Drug Discontinuation9
SecondaryClinical Success at 9 Months

Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 9-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia

Time frame:
9 months after start of treatment
Reported as:
Count of participants · Participants
Clinical Success at 9 Months
ParticipantsCEM-102 (Sodium Fusidate)
Clinical Success15
Clinical Failure11
Indeterminate4
SecondaryClinical Success at 12 Months

Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 12-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia

Time frame:
12 months after start of treatment
Reported as:
Count of participants · Participants
Clinical Success at 12 Months
ParticipantsCEM-102 (Sodium Fusidate)
Clinical Success10
Clinical Failure15
Indeterminate5
SecondaryClinical Success at 15 Months

Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 15-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia

Time frame:
15 months after start of treatment
Reported as:
Count of participants · Participants
Clinical Success at 15 Months
ParticipantsCEM-102 (Sodium Fusidate)
Clinical Success8
Clinical Failure17
Indeterminate5
SecondaryClinical Success at 18 Months

Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 18-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia

Time frame:
18 months after start of treatment
Reported as:
Count of participants · Participants
Clinical Success at 18 Months
ParticipantsCEM-102 (Sodium Fusidate)
Clinical Success8
Clinical Failure16
Indeterminate6
SecondaryClinical Success at 21 Months

Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 21-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia

Time frame:
21 months after start of treatment
Reported as:
Count of participants · Participants
Clinical Success at 21 Months
ParticipantsCEM-102 (Sodium Fusidate)
Clinical Success6
Clinical Failure17
Indeterminate7
SecondaryClinical Success at 24 Months

Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 24-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia

Time frame:
24 months after start of treatment
Reported as:
Count of participants · Participants
Clinical Success at 24 Months
ParticipantsCEM-102 (Sodium Fusidate)
Clinical Success7
Clinical Failure17
Indeterminate6

Adverse events

Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CEM-102 (Sodium Fusidate)0/30 (0%)15/30 (50%)27/30 (90%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventCEM-102 (Sodium Fusidate)
Device related infectionInfections and infestations4/30
Cardiac failure congestiveCardiac disorders3/30
Atrial fibrillationCardiac disorders2/30
SyncopeNervous system disorders2/30
BradycardiaCardiac disorders1/30
Gastrointestinal haemorrhageGastrointestinal disorders1/30
Arthritis infectiveInfections and infestations1/30
DiverticulitisInfections and infestations1/30
PneumoniaInfections and infestations1/30
PyelonephritisInfections and infestations1/30
Most frequent other events
Showing 10 of 30
Most frequent other events
EventCEM-102 (Sodium Fusidate)
Urinary tract infectionInfections and infestations9/30
AnaemiaBlood and lymphatic system disorders4/30
NauseaGastrointestinal disorders4/30
Oedema peripheralGeneral disorders4/30
Peripheral swellingGeneral disorders4/30
PyrexiaGeneral disorders4/30
DyspepsiaGastrointestinal disorders3/30
HypokalemiaMetabolism and nutrition disorders3/30
ArthralgiaMusculoskeletal and connective tissue disorders3/30
Vision blurredEye disorders2/30

Baseline characteristics

Intent-to-Treat (ITT) Population included all subjects who provided informed consent, met all eligibility criteria, and were enrolled in the study.

Age, Continuous
Age, Continuous(years)CEM-102 (Sodium Fusidate)
Mean61 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)CEM-102 (Sodium Fusidate)
Female10
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CEM-102 (Sodium Fusidate)
Hispanic or Latino2
Not Hispanic or Latino28
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CEM-102 (Sodium Fusidate)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White27
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)CEM-102 (Sodium Fusidate)
United States30
Height
Height(cm)CEM-102 (Sodium Fusidate)
Mean174.5 ± 11.54
Weight
Weight(kg)CEM-102 (Sodium Fusidate)
Mean87.4 ± 22.12
BMI
BMI(kg/m2)CEM-102 (Sodium Fusidate)
Mean28.7 ± 6.79

3 further baseline measures are reported on the registry.

08

Study locations

19 sites
  • Fountain Valley, California 92708, United States
  • San Dimas, California 91773, United States
  • Sylmar, California 91432, United States
  • Torrance, California 90502, United States
  • Tamarac, Florida 33321, United States
  • Springfield, Illinois 62703, United States
  • Louisville, Kentucky 40202, United States
  • Baltimore, Maryland 21218, United States
  • Boston, Massachusetts 02111, United States
  • Detroit, Michigan 48202, United States
  • Butte, Montana 59701, United States
  • Somers Point, New Jersey 08244, United States
  • Charlotte, North Carolina 28207, United States
  • Cincinnati, Ohio 45219, United States
  • Cleveland, Ohio 44195, United States
  • Haverford, Pennsylvania 19041, United States
  • Malvern, Pennsylvania 19355, United States
  • Philadelphia, Pennsylvania 19107, United States
  • Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Oct 2017 and a completion of Feb 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2020, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2015
First posted
Oct 6, 2015
Start
Dec 2015
Primary completionActual
Oct 17, 2017
CompletionActual
Feb 21, 2019
Results first posted
Jan 30, 2020
Last update
Jan 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02569541
Lead sponsor
Arrevus Inc.
Responsible party
Sponsor
First posted
Oct 6, 2015
Start date
Dec 2015
Primary completion
Oct 17, 2017
Completion
Feb 21, 2019
Results posted
Jan 30, 2020
Last update
Jan 30, 2020

Study contacts

Robert Dobbins, MD, PhD
study director · Melinta Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fusidic Acid

Start the discussion